Efficacy of an orally administered combination of hyaluronic acid, chondroitin sulfate, curcumin and quercetin for the prevention of recurrent urinary tract infections in postmenopausal women

  • M. Torella
    Correspondence
    Corresponding author.
    Affiliations
    Department of Women, Children and of General and Specialized Surgery – Second University of Studies of Naples Largo Madonna delle Grazie 1, 80138 Naples, Italy
    Search for articles by this author
  • F. Del Deo
    Affiliations
    Department of Women, Children and of General and Specialized Surgery – Second University of Studies of Naples Largo Madonna delle Grazie 1, 80138 Naples, Italy
    Search for articles by this author
  • A. Grimaldi
    Affiliations
    Department of Women, Children and of General and Specialized Surgery – Second University of Studies of Naples Largo Madonna delle Grazie 1, 80138 Naples, Italy
    Search for articles by this author
  • S.A. Iervolino
    Affiliations
    Department of Women, Children and of General and Specialized Surgery – Second University of Studies of Naples Largo Madonna delle Grazie 1, 80138 Naples, Italy
    Search for articles by this author
  • M. Pezzella
    Affiliations
    Department of Women, Children and of General and Specialized Surgery – Second University of Studies of Naples Largo Madonna delle Grazie 1, 80138 Naples, Italy
    Search for articles by this author
  • C. Tammaro
    Affiliations
    Department of Women, Children and of General and Specialized Surgery – Second University of Studies of Naples Largo Madonna delle Grazie 1, 80138 Naples, Italy
    Search for articles by this author
  • P. Gallo
    Affiliations
    Maternal and Child Department – Cremona Hospital – A. O. Istituti Ospitalieri di Cremona Viale Concordia 1, 26100 Cremona, Italy
    Search for articles by this author
  • C. Rappa
    Affiliations
    Department of Obstetrics and Gynaecology – Buon Consiglio Fatebenefratelli Hospital Via Alessandro Manzoni 220, 80123 Naples, Italy
    Search for articles by this author
  • P. De Franciscis
    Affiliations
    Department of Women, Children and of General and Specialized Surgery – Second University of Studies of Naples Largo Madonna delle Grazie 1, 80138 Naples, Italy
    Search for articles by this author
  • N. Colacurci
    Affiliations
    Department of Women, Children and of General and Specialized Surgery – Second University of Studies of Naples Largo Madonna delle Grazie 1, 80138 Naples, Italy
    Search for articles by this author
Published:November 01, 2016DOI:https://doi.org/10.1016/j.ejogrb.2016.10.018

      Abstract

      Objective

      To assess whether the orally administered combination of hyaluronic acid (HA), chondroitin sulfate (CS), curcumin and quercetin could be effective in preventing recurrent cystitis in postmenopausal women and whether its efficacy was conditioned by the concurrent use of local estrogen therapy.

      Study design

      This was a prospective evaluation of 145 postmenopausal women consecutively recruited from the database of three different investigators. All women should have mild-to-moderate urogenital atrophy and a history of recurrent urinary tract infections (≥2 episodes within 6 months or ≥3 episodes within 12 months documented by positive urine cultures) during the last year. Patients were assigned to three different therapeutic regimens: the first group was treated only with vaginal estrogens, the second group only with HA, CS, curcumin and quercetin per os, and the third group was treated with HA, CS, curcumin and quercetin associated with local estrogens. We evaluated the number of patients with <2 infective episodes in the 6-month follow-up and <3 episodes in the 12-month follow-up (main aim definition) and the reduction of related symptoms through a Visual Analog Scale (VAS) and the Pelvic Pain and Urgency/Frequency (PUF) patient symptom scale. Student's t-test and chi-squared test were used for data analysis as appropriate.

      Results

      At 6-month follow up, the main aim rate was 8%, 11.1% and 25% in the three groups, respectively (p < 0.05 compared to baseline only in group 3). Although the reduction in the number of recurrent episodes became significant in all groups at 1 year follow-up, the main aim rate was almost double in women receiving both local estrogens and oral therapy (group 3) compared to those receiving single treatments. The improvement of related symptoms was significant in all groups at 12-month follow-up.

      Conclusions

      In postmenopausal women, the combination of HA, CS, curcumin and quercetin per os was effective in preventing recurrent urinary tract infections, especially if administered with vaginal estrogen therapy.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Salvatore S.
        • Salvatore S.
        • Cattoni E.
        • et al.
        Urinary tract infections in women.
        Eur J Obstet Gynecol Reprod Biol. 2011; 156: 131-1366
        • Ronald A.
        The etiology of urinary tract infection: traditional and emerging pathogens.
        Am J Med. 2002; 113: 14S-19S
        • Naber K.G.
        • Bergman B.
        • Bishop M.C.
        • et al.
        EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU).
        Eur Urol. 2001; 40: 576-58888
        • Foxman B.
        • Gillespie B.
        • Koopman J.
        • et al.
        Risk factors for second urinary tract infection among college women.
        Am J Epidemiol. 2000; 151: 1194-1205205
        • Iosif C.S.
        • Bekassy Z.
        Prevalence of genito-urinary symptoms in the late menopause.
        Acta Obstet Gynecol Scand. 1984; 63: 257-26060
        • Raz R.
        • Gennesin Y.
        • Wasser J.
        • et al.
        Recurrent urinary tract infections in postmenopausal women.
        Clin Infect Dis. 2000; 30: 152-1566
        • Robinson D.
        • Cardozo L.
        Estrogens and the lower urinary tract.
        Neurourol Urodyn. 2011; 30: 754-7577
        • Perrotta C.
        • Aznar M.
        • Mejia R.
        • Albert X.
        • Ng C.W.
        Oestrogens for preventing recurrent urinary tract infection in postmenopausal women.
        Cochrane Database Syst Rev. 2008; : CD005131
        • Nickel J.C.
        • Hanno P.
        • Kumar K.
        • Thomas H.
        Second multicenter, randomized, double-blind, parallel-group evaluation of effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome.
        Urology. 2012; 79: 1220-12244
        • Porru D.
        • Leva F.
        • Parmigiani A.
        • et al.
        Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis.
        Int Urogynecol J. 2012; 23: 1193-11999
        • Madersbacher H.
        • van Ophoven A.
        • van Kerrebroeck P.E.
        GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans – a review.
        Neurourol Urodyn. 2013; 32: 9-18
        • Damiano R.
        • Quarto G.
        • Bava I.
        • et al.
        Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial.
        Eur Urol. 2011; 59: 645-65151
        • De Vita D.
        • Antell H.
        • Giordano S.
        Effectiveness of intravesical hyaluronic acid with or without chondroitin sulfate for recurrent bacterial cystitis in adult women: a meta-analysis.
        Int Urogynecol J. 2013; 24: 545-55252
        • Cicione A.
        • Cantiello F.
        • Ucciero G.
        • et al.
        Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: results from a multicentre survey.
        Can Urol Assoc J. 2014; 8: E721-E7277
        • Gugliotta G.
        • Calagna G.
        • Adile G.
        • et al.
        Is intravesical instillation of hyaluronic acid and chondroitin sulfate useful in preventing recurrent bacterial cystitis? A multicenter case control analysis.
        Taiwan J Obstet Gynecol. 2015; 54: 537-54040
        • Ciani O.
        • Arendsen E.
        • Romancik M.
        • et al.
        Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study.
        BMJ Open. 2016; 6: e009669
        • Bachmann G.
        Urogenital ageing: an old problem newly recognized.
        Maturitas. 1995; 22: S1-S5
        • Bump R.C.
        • Mattiasson A.
        • Bø K.
        • et al.
        The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction.
        Am J Obstet Gynecol. 1996; 175: 10-177
        • Parsons C.L.
        • Dell J.
        • Stanford E.J.
        • et al.
        Increased prevalence of interstitial cystitis: previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivity.
        Urology. 2002; 60: 573-5788
        • Elliott C.S.
        • Payne C.K.
        Interstitial cystitis and the overlap with overactive bladder.
        Curr Urol Rep. 2012; 13: 319-32626
        • De Vita D.
        • Giordano S.
        Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study.
        Int Urogynecol J. 2012; 23: 1707-171313
        • Torella M.
        • Schettino M.T.
        • Salvatore S.
        • Serati M.
        • De Franciscis P.
        • Colacurci N.
        Intravesical therapy in recurrent cystitis: a multi-center experience.
        J Infect Chemother. 2013; 19: 920-9255
        • Kerrn M.B.
        • Struve C.
        • Blom J.
        • Frimodt-Møller N.
        • Krogfelt K.A.
        Intracellular persistence of Escherichia coli in urinary bladders from mecillinam-treated mice.
        J Antimicrob Chemother. 2005; 55: 383-3866
        • Crespy V.
        • Morand C.
        • Manach C.
        • Besson C.
        • Demigne C.
        • Remesy C.
        Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen.
        Am J Physiol. 1999; 277: G120-G1266
        • Moon J.H.
        • Tsushida T.
        • Nakahara K.
        • Terao J.
        Identification of quercetin 3-O-beta-d-glucuronide as an antioxidative metabolite in rat plasma after oral administration of quercetin.
        Free Radic Biol Med. 2001; 30: 1274-128585
        • Park H.H.
        • Lee S.
        • Son H.Y.
        • et al.
        Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells.
        Arch Pharm Res. 2008; 31: 1303-131111
        • Yan X.M.
        • Joo M.J.
        • Lim J.C.
        • et al.
        The effect of quercetin-3-O-β-d-glucuronopyranoside on indomethacin-induced gastric damage in rats via induction of mucus secretion and down-regulation of ICAM-1 expression.
        Arch Pharm Res. 2011; 34: 1527-153434
        • Shirai M.
        • Moon J.H.
        • Tsushida T.
        • Terao J.
        Inhibitory effect of a quercetin metabolite, quercetin 3-O-beta-d-glucuronide, on lipid peroxidation in liposomal membranes.
        J Agric Food Chem. 2001; 49: 5602-56088
        • Pan M.H.
        • Huang T.M.
        • Lin J.K.
        Biotransformation of curcumin through reduction and glucuronidation in mice.
        Drug Metab Dispos. 1999; 27: 486-49494
        • Osawa T.
        • Sugiyama Y.
        • Inayoshi M.
        • Kawakishi S.
        Antioxidative activity of tetrahydrocurcuminoids.
        Biosci Biotechnol Biochem. 1995; 59: 1609-161212
        • Satoskar R.R.
        • Shah S.J.
        • Shenoy S.G.
        Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation.
        Int J Clin Pharmacol Ther Toxicol. 1986; 24: 651-6544
        • Zhi L.
        • Dong L.
        • Kong D.
        • et al.
        Curcumin acts via transient receptor potential vanilloid-1 receptors to inhibit gut nociception and reverses visceral hyperalgesia.
        Neurogastroenterol Motil. 2013; 25: e429-e44040
        • Robinson D.
        • Toozs-Hobson P.
        • Cardozo L.
        The effect of hormones on the lower urinary tract.
        Menopause Int. 2013; 19: 155-16262